Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

STEMEXPRESS, LLC

UEI: V6D4CLG1QU37CAGE: 5VLJ3

STEMEXPRESS, LLC is a federal contractor, registered under UEI V6D4CLG1QU37 and CAGE code 5VLJ3. It has been awarded $204,948 in federal contracts. Primary work spans Blood and Organ Banks, Biological Product (except Diagnostic) Manufacturing, and Medical Laboratories. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Phone+1 (555) 000-0000

Websitewww.cgt.global

Address123 Main St, City, ST 12345

Registration

UEI Code

V6D4CLG1QU37

CAGE Code

5VLJ3

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationLimited Liability CompanyWoman-Owned BusinessWomen-Owned Small Business

NAICS Codes

325414Biological Product (except Diagnostic) Manufacturing

541611Administrative Management and General Management Consulting Services

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

541720Research and Development in the Social Sciences and Humanities

+2 more

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

STEMEXPRESS, LLC specializes in the procurement, handling, and distribution of human biological specimens for advanced biomedical research and diagnostic development. Their core capabilities center on the secure logistics and quality-controlled supply of donor-derived blood and serum samples, partic...

Key Performance Metrics

Awards Count

8

All time

Active

0

Currently performing

Completed

8

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$204.9K100%

Awards by NAICS

621991 - Blood and Organ Banks$98.7K48.1%325414 - Biological Product (except Diagnostic) Manufacturing$51.4K25.1%621511 - Medical Laboratories$42.9K20.9%541714 - Research and Development in Biotechnology (except Nanobiotechnology)$12.0K5.9%

Awards by Agency Over Time

Awards by Place of Performance

Compete with STEMEXPRESS, LLC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for STEMEXPRESS, LLC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in STEMEXPRESS, LLC's top NAICS codes and agencies

Comprehensive Drug Screening and Laboratory Analysis

POSTED

about 3 hours ago

DEADLINE

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

Custom Homing Peptide Synthesis and AAV Capsid ModificationThis subcontract for the Department of Veterans Affairs, specifically supporting the Harry S Truman Memorial Veterans Hospital, involves the synthesis of targeting peptides and genetic engineering services. The scope of work includes designing homing peptides, modifying AAV capsid genomes for peptide display, and producing modified viral vector prototypes. These activities are to be conducted using molecular cloning tools and DNA/RNA synthesis platforms within BSL-2 facilities. The selected provider must hold BSL-2 certification to deliver the required modified AAV vector constructs and synthesized peptide sequences. Performance of the contract will take place in Columbia, Missouri, under NAICS code 325414. The solicitation was posted on October 21, 2026, with a response deadline of November 4, 2026.

Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

Accredited DNA Testing ProviderThis subcontract for the City and County of Swansea requires an accredited DNA testing provider to support safeguarding and social care projects. The selected provider will be responsible for the end-to-end testing process, including identity verification, the collection of buccal swab samples, and strict chain of custody management. Technical requirements include performing DNA profiling and comparison within accredited sequencing laboratories to ensure the highest standards of accuracy. Beyond laboratory analysis, the provider must deliver formal verified reports and provide expert witness testimony for court hearings. This opportunity was posted on October 20, 2026, with a response deadline of November 16, 2026. The services fall under NAICS code 621511, focusing on specialized medical diagnostic services to support legal and social care outcomes.

City & County of Swansea

POSTED

DEADLINE

Accredited Drug and Alcohol Testing ProviderThis subcontract agreement establishes an Accredited Drug and Alcohol Testing Provider to support prime contractors on statutory projects for the City and County of Swansea. The selected provider is responsible for the end-to-end testing process, including field or clinic-based sample collection, the management of a secure chain of custody to ensure legal admissibility, and comprehensive laboratory analysis. To maintain these standards, the provider must utilize accredited laboratory facilities and secure transport containers. Beyond technical testing, the provider is required to deliver professional test reports and offer expert interpretation of results. This scope of work extends to legal support, requiring the provider to furnish expert witness testimony during legal proceedings. Interested parties must respond by November 16, 2026, in accordance with the solicitation posted on October 20, 2026.

City & County of Swansea

POSTED

DEADLINE

Framework Agreement for DNA, Drug and Alcohol Testing Services

Solicitation # CCS/26/257

The City and County of Swansea is establishing a Framework Agreement under solicitation CCS/26/257 for accredited testing services to support statutory functions, including social care, safeguarding, and legal proceedings. The framework is divided into two lots: Lot 1 for Drug and Alcohol Testing Services and Lot 2 for DNA Testing Services, with each lot having an estimated value of 350,000 GBP excluding VAT. The scope of work includes identity verification for DNA testing and expert witness support where required. The agreement is scheduled to run from January 11, 2027, to January 10, 2032, with an option to extend for an additional 24 months through January 10, 2034. A maximum of six suppliers may be appointed to the framework, and the council may award contracts through either direct award or mini-competition. This procurement is designated as a light touch regime and is open to small and medium-sized enterprises as well as voluntary, community, and social enterprises. Interested parties must submit their tenders electronically via the eTenderWales portal by November 16, 2026, at 12:00pm. Submissions are accepted in both English and Welsh, and bidders may apply for one or both available lots.

City & County of Swansea

POSTED

DEADLINE

STAT Clinical Laboratory Testing & AnalysisThis subcontract for STAT Clinical Laboratory Testing and Analysis supports prime contractors on Department of Veterans Affairs healthcare system projects. The selected provider will perform 24/7/365 analysis and monitoring of patient specimens, ensuring immediate notification of critical results and the delivery of final written reports within five working days. To qualify, the provider must employ board-certified pathologists and maintain a NYS DOH Clinical Laboratory Permit and a CLIA license. Additionally, the facility must hold accreditation from either the College of American Pathologists or the Joint Commission. This opportunity is categorized under NAICS code 621511 and is managed by the Department of Veterans Affairs Network Contract Office 02.

242-NETWORK Contract Office 02 (36C242)

POSTED

DEADLINE

Q301--FY27 (BASE+4) STAT Laboratory Testing - Syracuse (VA-27-00010334)

Solicitation # 36C24227Q0069

The Department of Veterans Affairs VISN 2 Network Contracting Office intends to award a firm fixed-price contract for STAT laboratory testing services at the Syracuse VA Medical Center. The proposed contract structure includes a base period followed by four option periods. The government intends to sole source this requirement to University Pathologists Laboratories under FAR 6.302-1(a)(2), though this special notice serves as market research to identify other capable providers, including various small business socioeconomic categories. The scope of work involves the 24/7, 365-day-a-year analysis, monitoring, and reporting of clinical and surgical specimens, utilizing advanced methods such as electron microscopy and molecular studies. Key operational requirements include picking up specimens within 30 minutes of a request and delivering final written reports within five working days. Critical results require immediate notification to authorized providers. To be eligible, the contractor must employ board-certified pathologists and accredited technologists and maintain mandatory certifications, including a NYS Department of Health Clinical Laboratory Permit, a CLIA license, and CAP or Joint Commission accreditation. This acquisition falls under NAICS code 621511. Interested parties must provide documentation of their technical expertise and socioeconomic status to the contracting officer within 10 calendar days of the notice publication.

242-NETWORK Contract Office 02 (36C242)

POSTED

DEADLINE

Specialized Cell Source & Biobank SupplyThis subcontract opportunity with the National Institutes of Health, under the Department of Health and Human Services, focuses on the supply and qualification of human cell sources and biological resources for prime contractors working on NIAID infectious disease projects. The selected provider will be responsible for sourcing, characterizing, and qualifying primary cells or human cell lines that represent diverse human variability, utilizing genomic characterization tools and cryogenic storage to ensure quality and stability. The scope of work includes performing essential qualification of cell sources as a project benchmark and delivering fully characterized tissue samples or cell lines. Interested parties should note that the response deadline is January 29, 2027, and the project falls under NAICS code 621511.

National Institutes Of Health

POSTED

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Forensic Toxicology Laboratory ServicesThis subcontract for Forensic Toxicology Laboratory Services supports Florida Department of Transportation drug testing projects by providing professional analysis of collected drug and alcohol specimens for prime contractors. The selected provider is responsible for analyzing specimens for controlled substances, processing split samples, and delivering all test results and reports to the Medical Review Officer. To qualify, the provider must operate a certified forensic toxicology laboratory that adheres to all USDOT and FMCSA standards. This opportunity falls under NAICS code 621511, with a response deadline set for November 4, 2026.

Florida Department of Transportation

POSTED

DEADLINE